Sigyn Therapeutics, Inc. (SIGY)
OTCMKTS · Delayed Price · Currency is USD
0.0250
-0.0050 (-16.67%)
At close: Aug 19, 2026
Sigyn Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 0.09 | 0.01 | 0.01 | 0.01 | 0.34 | 0.08 |
Cash & Short-Term Investments | 0.09 | 0.01 | 0.01 | 0.01 | 0.34 | 0.08 |
Cash Growth | -48.07% | 3.88% | 39.90% | -97.55% | 303.97% | - |
Inventory | - | - | 0.05 | 0.05 | 0.05 | 0.59 |
Other Current Assets | - | 0.01 | 0.06 | 0.01 | 0 | - |
Total Current Assets | 0.09 | 0.02 | 0.12 | 0.07 | 0.39 | 0.67 |
Property, Plant & Equipment | - | 0.12 | 0.18 | 0.24 | 0.29 | 0 |
Other Intangible Assets | - | - | - | 0 | 0.01 | 0.02 |
Other Long-Term Assets | 0.05 | 0.07 | 0.02 | 0.02 | 0.02 | - |
Total Assets | 0.14 | 0.21 | 0.32 | 0.33 | 0.71 | 0.69 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 0.77 | 0.61 | 0.46 | 0.33 | 0.04 | 0.02 |
Accrued Expenses | 2.28 | 1.87 | 0.79 | 0.03 | 0 | 0.06 |
Short-Term Debt | 0.75 | 2.07 | 2.29 | 1.64 | 0.65 | 0.52 |
Current Portion of Leases | - | 0.07 | 0.06 | 0.05 | 0.05 | - |
Other Current Liabilities | 0.19 | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 3.99 | 4.61 | 3.61 | 2.05 | 0.73 | 0.59 |
Long-Term Leases | - | 0.06 | 0.13 | 0.19 | 0.24 | - |
Total Liabilities | 6.05 | 4.67 | 3.73 | 2.24 | 0.97 | 0.59 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 11.46 | 10.22 | 7.93 | 5.29 | 4 | 1.36 |
Retained Earnings | -17.38 | -14.68 | -11.34 | -7.2 | -4.27 | -1.26 |
Shareholders' Equity | -5.92 | -4.46 | -3.41 | -1.9 | -0.26 | 0.1 |
Total Liabilities & Equity | 0.14 | 0.21 | 0.32 | 0.33 | 0.71 | 0.69 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | 2.81 | 2.19 | 2.48 | 1.88 | 0.93 | 0.52 |
Net Cash (Debt) | -2.73 | -2.18 | -2.47 | -1.87 | -0.59 | -0.43 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -1.70 | -1.64 | -2.24 | -2.00 | -0.65 | -2.36 |
Filing Date Shares Outstanding | 1.61 | 1.61 | 1.22 | 1.07 | 0.93 | 0.88 |
Total Common Shares Outstanding | 1.61 | 1.61 | 1.29 | 0.96 | 0.93 | 0.88 |
Working Capital | -3.9 | -4.59 | -3.49 | -1.98 | -0.34 | 0.08 |
Book Value Per Share | -3.69 | -2.78 | -2.65 | -1.99 | -0.28 | 0.11 |
Tangible Book Value | -5.92 | -4.46 | -3.41 | -1.91 | -0.27 | 0.08 |
Tangible Book Value Per Share | -3.69 | -2.78 | -2.65 | -1.99 | -0.29 | 0.09 |
Machinery | - | 0.03 | 0.03 | 0.03 | 0.03 | 0 |